What question did this study set out to answer?

This review aims to explore recent advancements and challenges in cell-based therapies for type 1 diabetes, focusing on stem cell-derived islets.

July 4, 2026CureusOpen Access

Cell-Based Therapies for Type 1 Diabetes: A Narrative Review of Stem Cell-Derived Islets, Encapsulation Strategies, and Recent Clinical Trials

View Full Paper

Ask AI

Bookmark

This review aims to explore recent advancements and challenges in cell-based therapies for type 1 diabetes, focusing on stem cell-derived islets.
Narrative review of recent clinical trials and technological innovations in cell-based therapies for T1D.
Emphasis on stem cell-derived islet generation and encapsulation strategies for immunoprotection.
Analysis of landmark clinical trials and developments in encapsulation technologies.
Early trials show potential for insulin independence and glucose-responsive C-peptide secretion.
Encapsulation technologies aim to protect grafts from immune rejection and eliminate systemic immunosuppression.
Challenges identified include fibrosis, vascularization, long-term graft survival, and scalable manufacturing.

No takes yet. Share an insight, caveat, or question.

Narrative review highlights innovations in stem cell-derived islets and recent clinical trials for type 1 diabetes, suggesting future directions.

Guttikonda et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Narrative review highlights innovations in stem cell-derived islets and recent clinical trials for type 1 diabetes, suggesting future directions.